Imatinib [clinicaltrials_resource:daa3ac9ba968405a1d6671857c44fe86]
An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints [clinicaltrials:NCT01216085]Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy [clinicaltrials:NCT01316458]Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib [clinicaltrials:NCT01564836]clinicaltrials:NCT01844765
condition [clinicaltrials_vocabulary:condition]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
clinicaltrials:NCT00002514clinicaltrials:NCT00004932STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00006052]STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa [clinicaltrials:NCT00006053]STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia [clinicaltrials:NCT00006343]STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma [clinicaltrials:NCT00006357]STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis [clinicaltrials:NCT00006475]Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor [clinicaltrials:NCT00009906]Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma [clinicaltrials:NCT00010049]STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00015834]clinicaltrials:NCT00015847STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia [clinicaltrials:NCT00015860]clinicaltrials:NCT00021229clinicaltrials:NCT00022490Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia [clinicaltrials:NCT00022737]Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery [clinicaltrials:NCT00025246]Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction [clinicaltrials:NCT00025415]Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure [clinicaltrials:NCT00026169]clinicaltrials:NCT00027586clinicaltrials:NCT00028002Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia [clinicaltrials:NCT00028847]Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00030394]Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood [clinicaltrials:NCT00030667]Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma [clinicaltrials:NCT00031915]Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib [clinicaltrials:NCT00036738]Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer [clinicaltrials:NCT00036751]Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer [clinicaltrials:NCT00038194]clinicaltrials:NCT00038610clinicaltrials:NCT00038649clinicaltrials:NCT00038675Imatinib Mesylate in Treating Patients With Gliomas [clinicaltrials:NCT00039364]clinicaltrials:NCT00039377Imatinib Mesylate in Treating Patients With Myelofibrosis [clinicaltrials:NCT00039416]Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor [clinicaltrials:NCT00039585]clinicaltrials:NCT00040105Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer [clinicaltrials:NCT00041041]Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery [clinicaltrials:NCT00041197]Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer [clinicaltrials:NCT00041340]Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [clinicaltrials:NCT00041990]Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [clinicaltrials:NCT00042003]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Imatinib [clinicaltrials_resource:daa3ac9ba968405a1d6671857c44fe86]
Bio2RDF identifier
daa3ac9ba968405a1d6671857c44fe86
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:daa3ac9ba968405a1d6671857c44fe86
identifier
clinicaltrials_resource:daa3ac9ba968405a1d6671857c44fe86
title
Imatinib
@en
type
label
Imatinib [clinicaltrials_resource:daa3ac9ba968405a1d6671857c44fe86]
@en